Thanks Assuming the assay is good then we definitely learned that pgRNA is not a good biomarker to use, at least in the time frame used in the protocol ( it could be that you need to be suppressed for longer to stop therapy) More likely someone is going to have to come up with another biomarker
liver biopsies are unduly invasive
agreed and not practical for general use. However I would think you can use a liver biopsy to assess cccDNA, so you can in a limited pt population study correlation of biomarkers with liver cccDNA before you use that biomarker as a stoppage criterion. Perhaps that could be a way forward? Again I agree w you that surface antigen may not be ideal
News 
Market Data 
Discover 
